AstraZeneca profits fell sharply in the first half on ballooning costs linked to its takeover of US biotech firm Alexion.Check pharmacy business for full news.
Tag: AstraZeneca-news
Global pharmaceutical and biotechnology company AstraZeneca has signed an agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against cancer proteins.
The collaboration, announced today (January 13), will focus on a class of proteins called transcription factors, which can regulate important cellular processes including cell growth and survival.
Many transcription factors have been identified earlier, but were considered ‘undruggable’ using conventional drug discovery approaches, the company said in a statement.
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: “Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments.
“Scorpion’s innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets.”
Prince Charles formally opened a new 1 billion pound AstraZeneca research and development (R&D) facility in Cambridge on Tuesday (November 23), as the company aims to fuel the growth of its drug pipeline.
AstraZeneca has supplied two billion doses of its Covid-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against Covid-19 to market.
Prince Charles, son of Queen Elizabeth and heir to the throne, saw an exhibit on the pandemic and a demonstration of how augmented reality headsets can help with lab work, before hearing about the company’s net-zero targets.
“The last two years have been some of the most difficult of a generation,” Prince Charles said in a speech.
